Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02985242

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Diabetes Mellitus, Type II Clinical Trial

Official title:
SGLT2-inhibition With Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema (The SUPER-Trial)

Clinical Trial Summary

This is a prospective, randomized, active control, two-arm parallel, double-blind, monocenter phase IV clinical trial. The trial compares empagliflozin to glimepiride in patients with type 2 diabetes mellitus in addition to standard of care treatment.

Patients with type 2 diabetes mellitus who are between 18 and 80 years of age will be recruited for the clinical trial and randomly allocated to either receive empagliflozin or glimepiride.

The assumption of the study is that empagliflozin slows down diabetic retinopathy progression rate and thus a lower microaneurysm formation rate compared to subjects treated with glimepiride by substantially decreased cellular glucotoxicity will be achieved.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02985242
Study type Interventional
Source Hannover Medical School
Contact
Status Terminated
Phase Phase 4
Start date June 12, 2017
Completion date August 16, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT03596177 - A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus Phase 2
Completed NCT01728740 - Bioequivalence Study for Acarbose / Metformin FDC Phase 1
Completed NCT02648854 - Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers Phase 1
Recruiting NCT02347020 - Impact of Sleep and Meal Timing on Food Intake Regulation N/A
Completed NCT00577590 - Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM N/A
Completed NCT00094796 - Rosiglitazone to Reverse Metabolic Defects in Diabetes Phase 2
Completed NCT04830969 - Impact of Periodontal Therapy on Patients With Diabetes Phase 2
Completed NCT03112382 - Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus Phase 4
Recruiting NCT01197092 - The Effects of a Regenerative Mitochondrial Medication on Physiological Parameters in Case of Diabetes Mellitus Type II Phase 2
Completed NCT00649909 - Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients N/A
Terminated NCT00554697 - Diabetes Mellitus Type II and Tissue Oxygenation N/A
Not yet recruiting NCT05957224 - Differences in Postprandial Glucose Changes N/A
Active, not recruiting NCT02088658 - Technology Intensified Diabetes Education Study in African Americans N/A
Completed NCT00081328 - Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Phase 3
Completed NCT00482079 - A Study of MK0431 in Patients With Type 2 Diabetes (0431-010) Phase 2
Recruiting NCT04092738 - ´Sit Less, Move More` at Work: mHealth Intervention on Office Employees With Diabetes Type 2. N/A
Completed NCT03012074 - Episodic to Real-Time Care in Diabetes Self-Management N/A
Completed NCT02175537 - Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in Qatar N/A
Completed NCT01651065 - Micro-Clinic Obesity and Metabolic Risk Prevention Program N/A
Completed NCT00528918 - Comparison of Apidra to Regular Insulin in Hospitalized Patients N/A